Dual immunotherapy in liver-cancer (IMAGE)

The University of Hong Kong

Dual immunotherapy in liver-cancer

Caption

Dual immunotherapy in liver-cancer: Following the significant effects of the ‘dual immunotherapy’, the new combination treatment has been approved from the FDA, EMA and NMPA for previously untreated advanced HCC patients. The research team includes (from left) Professor Cheung Tan-to, Dr Thomas Yau Chung-cheung and Dr Ronald Leung Ching-yu.

Credit

The University of Hong Kong

Usage Restrictions

No restriction

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.